Back

Cancer Stem Cell-Associated Marker Expression in Chemotherapy-Treated Wilms Tumour

Mousavinejad, M.; Howell, L.; Murray, P.; Cheesman, E.; Pizer, B.; Losty, P. D.; Annavarapu, S.; Shukla, R.; Wilm, B.

2026-03-23 pathology
10.64898/2026.03.17.26348535 medRxiv
Show abstract

BackgroundWilms tumour (WT) relapse occurs more frequently in patients with blastemal-type WTs. The presence of cancer stem cells (CSCs) is linked to tumour survival and relapse, and CSCs may be found in greater numbers in blastemal cell foci. CSC-associated phenotypes have been described in untreated WT, but their persistence, organisation and relevance after neoadjuvant chemotherapy is unknown. MethodsWe analysed 23 formalin-fixed paraffin-embedded blocks from 18 chemotherapy-treated patients where WTs were enriched for viable blastema, using human fetal kidney as developmental control. Immunohistochemistry and -fluorescence analysis determined progenitor (PAX2, SIX2, CITED1) and CSC-associated (NCAM, ALDH1, CD133) marker expression. We qualitatively and semi-quantitatively evaluated spatial expression patterns and co-localisation across tumour compartments. ResultsPAX2 and SIX2 were co-expressed in blastema in most cases (15/18), with PAX2 expression higher at the periphery of blastemal foci and SIX2 expression found uniformly in central aspects. CITED1 expression was also associated with SIX2 in blastema tissues (14/18). NCAM was blastema-enriched (15/18) with higher central intensity, frequently adjacent to PAX2-expressing peripheral zones. ALDH1 expression was present across blastema and epithelium while NCAM-, ALDH1-double-positive cells were rarely observed (4/18). CD133 expression was less commonly seen (2/18), localising near epithelial/nephrogenic structures. ConclusionsAfter neoadjuvant chemotherapy, WT blastema retained overlapping but non-identical progenitor/CSC-associated marker landscapes with reproducible peripheral-centre gradients. These spatial arrangements suggest a blastemal niche for CSCs that may sustain a therapy-resistant state. Our analysis provides the foundation for future functional validation and molecular profiling to define key lineage relationships and therapeutic vulnerabilities in post-chemotherapy WT. [250/250 words]

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
Cancers
200 papers in training set
Top 0.1%
23.8%
2
PLOS ONE
4510 papers in training set
Top 16%
11.0%
3
Modern Pathology
21 papers in training set
Top 0.1%
7.2%
4
The Journal of Pathology
22 papers in training set
Top 0.1%
5.1%
5
Journal of Clinical Pathology
12 papers in training set
Top 0.1%
3.8%
50% of probability mass above
6
Scientific Reports
3102 papers in training set
Top 40%
3.2%
7
Frontiers in Oncology
95 papers in training set
Top 1%
2.9%
8
Molecular Oncology
50 papers in training set
Top 0.2%
2.8%
9
British Journal of Cancer
42 papers in training set
Top 0.6%
2.2%
10
Kidney International Reports
14 papers in training set
Top 0.2%
2.0%
11
The American Journal of Pathology
31 papers in training set
Top 0.2%
1.9%
12
Journal of Cellular and Molecular Medicine
18 papers in training set
Top 0.3%
1.9%
13
Kidney International
25 papers in training set
Top 0.3%
1.3%
14
Cells
232 papers in training set
Top 3%
1.3%
15
Disease Models & Mechanisms
119 papers in training set
Top 2%
1.3%
16
BMC Cancer
52 papers in training set
Top 2%
1.3%
17
Biology Methods and Protocols
53 papers in training set
Top 2%
1.0%
18
JNCI Cancer Spectrum
10 papers in training set
Top 0.4%
1.0%
19
JCI Insight
241 papers in training set
Top 6%
0.9%
20
eLife
5422 papers in training set
Top 52%
0.9%
21
International Journal of Cancer
42 papers in training set
Top 1%
0.8%
22
Clinical Cancer Research
58 papers in training set
Top 2%
0.8%
23
American Journal of Physiology-Gastrointestinal and Liver Physiology
11 papers in training set
Top 0.2%
0.8%
24
Neuro-Oncology
30 papers in training set
Top 0.7%
0.8%
25
Blood Cancer Journal
11 papers in training set
Top 0.3%
0.8%
26
Diagnostics
48 papers in training set
Top 2%
0.7%
27
Frontiers in Immunology
586 papers in training set
Top 9%
0.7%
28
BMC Medicine
163 papers in training set
Top 8%
0.7%
29
EMBO Molecular Medicine
85 papers in training set
Top 6%
0.5%
30
Laboratory Investigation
13 papers in training set
Top 0.4%
0.5%